AddedRisk Factors
Recent governmental actions and proposals relating to tariffs and other trade policies have created uncertainty about future trading arrangements and the possibility of jurisdictions imposing or increasing tariffs on certain goods. For example, certain governments (including the U.S. and other countries where we do business) have imposed or may impose tariffs on a wide range of products, raw materials and intermediate goods. The U.S. Supreme Court has invalidated some of the U.S. tariffs, but additional tariffs are anticipated to be imposed pursuant to the Trump Administration's ongoing U.S. trade investigation. Additional tariffs, or retaliatory measures by other countries in response, may be implemented at any time. Should these or similar tariffs remain in place (or be re-imposed or increased), or if additional tariffs or trade restrictions are enacted in the future, they could cause us or our future customers to face higher supply costs, delays or require us to switch suppliers. These actions could adversely affect our future margins, profitability, financial condition and results of operations.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
AddedRisk Factors
In addition, the pharmaceutical industry faces specific and evolving tariff-related risks. On April 2, 2026, the United States announced significant tariffs on certain pharmaceutical products, active pharmaceutical ingredients and key starting materials. These tariffs, which were imposed pursuant to a national security investigation under Section 232 of the Trade Expansion Act of 1962, will generally go into effect in September 2026. The tariffs, which range from 10% to 100% depending on type of product and country of origin, are also subject to a number of exemptions and exclusions. There is still significant uncertainty about implementation and application of the tariffs and the exemptions and exclusions as various elements of the tariff action remain to be determined in subsequent agency actions. These new U.S. tariffs may raise costs for drug products and inputs used in our clinical development programs or that our contract manufacturers and suppliers may procure in connection with manufacturing our product candidates.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
AddedRisk Factors
We cannot predict future changes in trade policy or the terms of any renegotiated trade agreements, nor can we determine the impact they may have on our business. Any such changes could have a material adverse effect on our business, financial condition and results of operations.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
AddedRisk Factors
negative impact on our commercial sales. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which economic climate and financial market conditions could adversely impact our business.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
RemovedRisk Factors
competing clinical trials for similar therapies or targeting patient populations meeting our patient eligibility criteria;
Read it in 10-K May 29, 2025 at sec.govopen_in_new
RemovedRisk Factors
clinicians’ and patients’ perceptions as to the potential advantages and side effects of the product candidate being studied in relation to other available therapies and product candidates;
Read it in 10-K May 29, 2025 at sec.govopen_in_new
RemovedRisk Factors
A breakthrough therapy is defined as a therapy that is intended, alone or in combination with one or more other therapies, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the therapy may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For therapies that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed on potentially less efficacious control regimens. Therapies designated as breakthrough therapies by the FDA may also be eligible for priority review and accelerated approval. Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe a product candidate meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a Breakthrough Therapy Designation for a product candidate may not result in a faster development process, review or approval compared to therapies considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if a product candidate qualifies as a breakthrough therapy, the FDA may later decide that such product candidate no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.
Read it in 10-K May 29, 2025 at sec.govopen_in_new
RemovedRisk Factors
Regulatory authorities in some jurisdictions, including the U.S., the U.K. and the European Economic Area (the “EEA”), may designate drugs and biologics for relatively small patient populations as orphan drugs. In the U.S., the FDA may designate a drug or biologic as an orphan drug if it is intended to treat a rare disease or condition, which is defined as a disease or condition that affects fewer than 200,000 individuals annually in the U.S. or for which there is no reasonable expectation that costs of research and development of the drug for the disease or condition can be recovered by sales of the drug in the U.S. Generally, if a product with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA from approving another marketing application for the same drug or biologic for the same orphan indication for that time period. In the U.S., in order for a product to receive orphan drug exclusivity, FDA must not have previously approved a drug considered the same drug for the same orphan indication, or the subsequent drug must be shown to be clinically superior to such a previously approved same drug. The applicable period of marketing exclusivity is seven years in the U.S. A similar market exclusivity scheme exists in the EEA. The European Commission, on the basis of a scientific opinion by the EMA’s Committee for Orphan Medicinal Products grants Orphan Drug Designation to promote the development of products that are intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than five in 10,000 persons in the E.U. Additionally, designation is granted for products intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition when, without incentives, it is unlikely that sales of the drug in the E.U. would be sufficient to justify the necessary investment in developing the drug or biological product. In any event, Orphan Drug Designation is granted only if there is no satisfactory method of diagnosis, prevention or treatment, or, if such a method exists, the medicine must be of significant benefit to those affected by the condition. Orphan designation in the E.U. entitles a party to certain benefits, such as scientific assistance (protocol assistance), financial incentives such as reduction of fees or fee waivers and ten years of market exclusivity following drug or biological product approval. This orphan market exclusivity period prevents the European Commission, EMA and the competent authorities of the E.U. Member States from accepting an application or granting marketing authorization for any similar medicinal product intended for the same orphan indication. The orphan market exclusivity applies in parallel to the “normal” data and market exclusivity in the EEA, whereby no company can make reference to (rely on) the innovator drug company’s preclinical and clinical data in order to obtain a marketing authorization for eight years from the date of the first approval of the innovator drug in the EEA and no generic or biosimilar drug can be marketed for ten years from the first approval of the innovator drug in the EEA; the innovator drug may qualify for an extra year’s protection. This additional one year of marketing exclusivity may be obtained where the innovator company is granted, during the first eight years of the ten years market exclusivity, a marketing authorization for a significant new indication for the relevant medicinal product. In such a situation, the generic or biosimilar company can only market their product after 11 years from the first grant of the innovator company’s marketing authorization for the product in the EEA.
Read it in 10-K May 29, 2025 at sec.govopen_in_new
RemovedRisk Factors
In June 2016, the electorate in the United Kingdom voted in favor of leaving the European Union (commonly referred to as Brexit). Thereafter, in March 2017, the country formally notified the European Union of its intention to withdraw pursuant to Article 50 of the Lisbon Treaty. The United Kingdom formally left the European Union in January 2020. A transition period began in February 2020, during which E.U. pharmaceutical law remained applicable in the United Kingdom. However, this ended in December 2020. In December 2020, the United Kingdom and European Union signed the Trade and Cooperation Agreement which includes an agreement on free trade between the two parties, although provides minimal provisions on medicinal products. Since that time, Great Britain operated a separate regulatory regime for medicinal products, although Northern Ireland continued to follow EU law. Further, in March 2023, an agreement was reached by the U.K. and EU (the “Windsor Agreement”), relating to post-Brexit trade issues in Northern Ireland, which has applied from January 2025. This seeks to simplify the supply of medicines between Great Britain and Northern Ireland and means EU legislation does not apply in all cases in Northern Ireland. Since the regulatory framework in the United Kingdom covering the quality, safety and efficacy of pharmaceutical products, clinical trials, marketing authorizations, commercial sales, and distribution of pharmaceutical products is derived from E.U. Directives and Regulations, Brexit could materially impact the future regulatory regime which applies to products and the approval of product candidates in the United Kingdom, as the U.K. legislation now has the potential to diverge from E.U. legislation. This continues to impact regulatory requirements for medicinal products and devices in the United Kingdom. The MHRA has published detailed guidance for industry and organizations on the position in the United Kingdom, and continues to update this as the United Kingdom’s regulatory position on medicinal products and medical devices evolves. There are also a number of ongoing consultations on the future legislation in the U.K., in particular in relation to the clinical trials and medical devices frameworks in the UK.
Read it in 10-K May 29, 2025 at sec.govopen_in_new
RemovedRisk Factors
the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future approved products;
Read it in 10-K May 29, 2025 at sec.govopen_in_new
RemovedRisk Factors
TEPEZZA (teprotumumab-trbw), an insulin-like growth factor-1 receptor inhibitor, a potential competitor to batoclimab;
Read it in 10-K May 29, 2025 at sec.govopen_in_new
RemovedRisk Factors
We also face competition from solutions that biopharmaceutical companies develop internally and from smaller companies that offer products and services directed at more specific markets than we target, enabling these smaller competitors to focus a greater proportion of their efforts and resources on these markets, in both healthcare technology and drug discovery.
Read it in 10-K May 29, 2025 at sec.govopen_in_new
RemovedRisk Factors
We may not hold a controlling stake in certain of our Vant affiliates and thus may not be able to direct our business or the development of our product candidates.
Read it in 10-K May 29, 2025 at sec.govopen_in_new
RemovedRisk Factors
In February 2022, Roivant’s subsidiary GSG and its affiliate Arbutus filed a lawsuit in the U.S. District Court for the District of Delaware against Moderna and an affiliate seeking damages for infringement of U.S. Patent Nos. 8,058,069, 8,492,359, 8,822,668, 9,364,435, 9,504,651, and 11,141,378 in the manufacture and sale of MRNA-1273, Moderna’s vaccine for COVID-19 (the “Moderna Action”). In November 2022, the District Court denied Moderna’s partial motion to dismiss pursuant to 28 U.S.C. § 1498(a) (“§ 1498”). In March 2023, following the submission of a Statement of Interest in the case by the U.S. Government, the court reaffirmed its prior decision and again ruled that the complaint should not be partially dismissed on the basis of § 1498. In February 2024, the court held a claim construction hearing on disputed terms within the claims of the asserted patents. On April 3, 2024, the court provided its claim construction ruling, in which it construed the disputed claim terms and agreed with GSG and Arbutus’ position on most of the disputed claim terms. Fact discovery in the Moderna Action has been completed, and expert discovery is on-going. The court in the Moderna Action has informed the parties that it plans to update the timing for the summary judgment phase and jury trial, previously scheduled for the second or third quarter of calendar year 2025 and September 2025, respectively.
Read it in 10-K May 29, 2025 at sec.govopen_in_new
RemovedRisk Factors
In addition, in March 2025, GSG and Arbutus filed five international lawsuits against Moderna targeting alleged infringing activity in 30 countries (the “International Cases”). These cases are:
Read it in 10-K May 29, 2025 at sec.govopen_in_new
RemovedRisk Factors
Canada: Federal Court of Canada File No. T-704-25, seeking a permanent injunction and damages or, if GSG so elects, an accounting of Moderna’s profits, attributable to infringement of Canadian Patent No. 2,721,333.
Read it in 10-K May 29, 2025 at sec.govopen_in_new
RewordedRisk Factors
Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA, EMA or other regulatory the competent authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a clinical benefit from using a product candidate, changes in governmental regulations or administrative actions, developments on trials conducted by us or our competitors for related technology that raises regulatory concerns about risk to patients of the technology broadly, or lack of adequate funding to continue the clinical trial. E.U.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
RewordedRisk Factors
Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct Member States and the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA, EMA U.K. or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a clinical benefit from using a product candidate, changes in governmental regulations or administrative actions, developments on trials conducted by us or our competitors for related technology that raises regulatory concerns about risk to patients of the technology broadly, or lack of adequate funding to continue the clinical trial.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
RewordedRisk Factors
As previously disclosed, our board of directors has authorized a repurchases of our common shares in an aggregate amount of up to $1.0 billion (excluding fees and expenses) (in addition to the previously disclosed common share repurchase program, program allowing for repurchases repurchase of our common shares in an aggregate amount of up to $1.5 billion (excluding fees and expenses) (the “2024 Repurchase Program”). expenses), which was fully exhausted as of June 30, 2025).
Read it in 10-K May 20, 2026 at sec.govopen_in_new
RewordedRisk Factors
The resolution of any dispute or disagreement involving contract interpretation disagreement that may arise in relation to the HanAll Agreement could affect the scope of our Immunovant's rights to the relevant intellectual property or technology, its product candidates or affect financial or other obligations under the relevant agreement, HanAll Agreement or other agreements related to the development and commercialization of Immunovant's product candidates, either of which could harm our business, financial condition, results of operations and prospects.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
RewordedRisk Factors
In addition, the proposal envisages legislation changes to the concept of unmet medical need and considers introducing novel additional rewards for orphan medicinal products considered to be “breakthrough orphan medicinal products” (i.e., orphan medicinal products addressing a high unmet medical need. disease with no current available medicinal treatment and which bring a clinically relevant reduction in morbidity or mortality).
Read it in 10-K May 20, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our Further, our computational drug discovery Vants, including VantAI, which uses machine learning to build computational models to generate new molecular entities for targets of interest, and Psivant, which uses molecular dynamics to design small molecules for highly validated hard-to-drug targets, efforts face competition from both established industry competitors and an increasing wave of competition in the in silico discovery and development worlds, including startups, large and mid-sized biopharmaceutical companies, large technology companies and others.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
RewordedRisk Factors
Following the Dermavant Transaction we We do not currently have any product candidates that have received marketing approval anywhere in the world commercial stage products and we do not expect to generate product revenues from the commercial sale of our product candidates in the near term. until we receive applicable regulatory approvals for one of our product candidates.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
RewordedRisk Factors
AI can present ethical issues and may subject us to new or heightened legal, regulatory, ethical or other challenges; and inappropriate or controversial data practices by developers and end-users, or other factors adversely affecting public opinion of AI, could impair the acceptance of AI solutions, including those incorporated in our businesses. challenges.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
RewordedRisk Factors
U.S. holders that own 10% or more of the combined voting power or value of our common shares may suffer adverse tax consequences because we and be subject to U.S. federal income taxation on our non-U.S. subsidiaries may be characterized as “controlled foreign corporations” (“CFCs”) under Section 957(a) of the Code. undistributed earnings.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
RewordedRisk Factors
These increased expenses, complexities and other challenges may make using and scaling the Vant model more challenging and costly than it would be for a traditional pharmaceutical company to both operate and expand the number of product candidates under development, which could have a material adverse effect on our consolidated business, financial condition, results of operations or prospects.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
RewordedRisk Factors
In addition, legislative, executive and regulatory proposals were recently enacted or are pending to, among other things, prevent drug shortages, improve pandemic preparedness and reduce the dependency of the U.S. on foreign supply chains and manufacturing; this may include the imposition of tariffs on foreign-manufactured products that we procure. procure as well as limitations on our ability to use biotechnology equipment or services produced or provided by select Chinese biotechnology companies in the performance of federal contracts or grants.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
RewordedRisk Factors
“Global intangible low-taxed income” GILTI may include most of the remainder of a CFC’s income over a deemed return on its tangible assets, and “net CFC tested income” generally is similar to GILTI, but is computed without accounting for any such deemed return on a CFC’s tangible assets.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
As a result, we cannot estimate with precision the extent of our any future profits or losses.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
The amount of cash available to return to shareholders, if any, can may vary significantly from period to period for a number of reasons, including, among other things, our results of operations, financial condition, cash requirements, contractual restrictions, applicable law and other factors that our board of directors may deem relevant.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, substantially increase the costs of commercializing our any product candidates in the future following regulatory approval, and could significantly harm our business, financial condition, results of operations and growth prospects.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
There is no assurance that our product candidates candidates, if approved, will achieve adequate coverage and reimbursement levels.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
The healthcare budgetary constraints in most countries have resulted in restrictions on the pricing and reimbursement of medicines, and generally a similar approach is taken in the U.K. where a key consideration is the affordability of drugs for treatment of patients under the National Health Service.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Our employment agreements provide that our employees could may leave our employment employ at any time.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
We do not have and may not obtain patent rights in all countries in which a market may exist.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
In that case, we anticipate that our corporate structure and intercompany transactions, including the manner in which we develop and use our intellectual property, will be organized so that we can achieve our business objectives in a tax-efficient manner and in compliance with applicable transfer pricing rules and regulations.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
If taxing authorities were to allocate income to a higher tax jurisdiction, subject our income to double taxation or assess interest and penalties, it would could increase its our consolidated tax liability, which could adversely affect our financial condition, results of operations and cash flows.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
As we intend to operate in numerous countries and taxing jurisdictions, the application of tax laws can be subject to diverging and sometimes conflicting interpretations by tax authorities of these jurisdictions.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
AddedMD&A
Gain on litigation settlement reflects a gain resulting from the settlement agreement (the “Settlement Agreement”) entered between our subsidiary, Genevant Sciences GmbH (“Genevant”), Arbutus Biopharma Corporation (together with Genevant, “Genevant/Arbutus”), and, solely for certain purposes, Genevant’s parent Genevant Sciences Ltd., and Moderna, Inc. and ModernaTx, Inc. (together, “Moderna”) in March 2026 to resolve all patent infringement litigation between Genevant/Arbutus and Moderna pending in the U.S. and internationally relating to Moderna’s unauthorized use of Genevant/Arbutus’ lipid nanoparticle (“LNP”) delivery technology in its vaccines, including SPIKEVAX. We recognized a gain on litigation settlement of $770.2 million during the year ended March 31, 2026 in the accompanying consolidated statements of operations for Genevant’s expected portion of the $950 million non-contingent, non-creditable, and non-refundable payment to be made by Moderna to Genevant and Arbutus on or before July 8, 2026 (the “Fixed Payment”). The allocation of this Fixed Payment is subject to adjustment upon final determination of actual litigation costs and expenses incurred. Refer to Note 5, “Recent Transactions and Developments” of our audited financial statements for further information regarding the Settlement Agreement.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
AddedMD&A
The increase of $21.6 million in personnel-related expenses, which is an unallocated internal cost, was primarily driven by higher headcount to support additional clinical studies for the anti-FcRn franchise activities at Immunovant and brepocitinib at Priovant. The $8.1 million increase in share-based compensation expense was primarily driven by the Priovant Exchange Offer. Refer to Note 9, “Share-Based Compensation and Other Compensation Plans” of our financial statements for further details.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
AddedMD&A
Our short-term and long-term liquidity requirements as of March 31, 2026 included obligations under our leases (see Note 11, “Leases” of our audited financial statements). As of March 31, 2026, our subsidiary, Immunovant, had an accumulated accrual of $42.5 million of non-cancelable contractual costs as a result of the discontinuation of batoclimab, of which $39.0 million was recognized as research and development expense during the year ended March 31, 2026. Beyond this, we do not currently have any other material contractually obligated minimum purchases or firm non-cancelable purchase commitments. We anticipate other purchases in the ordinary course of business and have other payment obligations as discussed below.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
AddedMD&A
•LNP Technology (Genevant): up to 20% of Royalty-Related Receipts (as defined in the Cross-License Agreement).
Read it in 10-K May 20, 2026 at sec.govopen_in_new
AddedMD&A
For the year ended March 31, 2026, cash used in operating activities decreased by $89.1 million to $750.3 million compared to $839.5 million for the year ended March 31, 2025. This decrease was primarily due to certain cost savings during the year ended March 31, 2026 as a result of the sale of Dermavant along with lower cash compensation during the year ended March 31, 2026 as a result of higher one-time cash awards made pursuant to the Senior Executive Compensation Program during the year ended March 31, 2025. These decreases were partially offset by lower cash receipts from revenues in part as a result of the sale of Dermavant, less interest income received and greater cash requirements to advance our existing research and development programs, including the anti-FcRn franchise and brepocitinib, during the year ended March 31, 2026.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
AddedMD&A
In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Updates (“ASU”) 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures,” which requires updates to the income tax disclosures related to the rate reconciliation and disaggregation of income taxes paid by jurisdiction. The amendments are effective for fiscal years beginning after December 15, 2024 and are applicable to our fiscal year beginning April 1, 2025, with early adoption permitted. The amendments should be applied prospectively, however retrospective application is permitted. We adopted this ASU prospectively for the fiscal year ended March 31, 2026. This resulted in expanded disclosures in line with the requirements of the ASU.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
AddedMD&A
In September 2025, the FASB issued ASU 2025-07, “Derivatives Scope Refinements and Scope Clarification for Share-Based Noncash Consideration from a Customer in a Revenue Contract”, which refines the scope of the guidance on derivatives in ASC 815 and clarifies the guidance on share-based payments from a customer in ASC 606. This guidance is effective for fiscal years and interim periods beginning after December 15, 2026, with early adoption permitted. These requirements may be applied prospectively or on a modified retrospective basis through a cumulative-effect adjustment to the opening balance of retained earnings. We early adopted this guidance during the quarter ended March 31, 2026. We applied the derivative scope refinements guidance on a modified retrospective basis and applied the share-based payments guidance on a prospective basis. The adoption of this guidance had no impact on our consolidated financial statements.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
RemovedMD&A
For the year ended March 31, 2023, loss from discontinued operations, net of tax also includes the gain on sale of common shares of Myovant Sciences Ltd. (“Myovant”) as a result of Sumitovant Biopharma Ltd.’s (“Sumitovant”) acquisition of the remaining noncontrolling interest in Myovant in March 2023. We were entitled to these shares of Myovant pursuant to the December 2019 transaction with Sumitomo Pharma Co., Ltd. (the “Sumitomo Transaction”) that included, among other things, the transfer of our ownership interest in five Vants to Sumitovant. The Sumitomo Transaction was presented as discontinued operations during the year ending March 31, 2020, and the right to receive certain common shares of Myovant was treated as a contingent consideration upon a sale of the business and accounted for as a gain contingency.
Read it in 10-K May 29, 2025 at sec.govopen_in_new
RemovedMD&A
Refer to Note 6, “Discontinued Operations” of our audited financial statements for further information.
Read it in 10-K May 29, 2025 at sec.govopen_in_new
RemovedMD&A
Gain on deconsolidation of subsidiaries was $3.1 million, $32.8 million, and $29.3 million for the years ended March 31, 2025, 2024 and 2023, respectively. The gain for the year ended March 31, 2025 resulted from the deconsolidation of a subsidiary in March 2025. The gain for the year ended March 31, 2024 resulted from the deconsolidation of certain subsidiaries, including VantAI Holdings, Inc. in July 2023 and Proteovant in August 2023. The gain for the year ended March 31, 2023 resulted from the deconsolidation of certain subsidiaries in November 2022 and July 2022.
Read it in 10-K May 29, 2025 at sec.govopen_in_new
RemovedMD&A
Our short-term and long-term liquidity requirements as of March 31, 2025 included:
Read it in 10-K May 29, 2025 at sec.govopen_in_new
RemovedMD&A
obligations under our leases (see Note 11, “Leases” of our audited financial statements); and
Read it in 10-K May 29, 2025 at sec.govopen_in_new
RemovedMD&A
certain commitments to Samsung Biologics Co., Ltd. (“Samsung”) pursuant to a Product Service Agreement (“PSA”) entered into between Immunovant and Samsung pursuant to which Samsung will manufacture and supply Immunovant with batoclimab drug substance for commercial sale, if approved, and perform other manufacturing-related services with respect to batoclimab. Upon execution of the PSA, Immunovant committed to purchase process performance qualification batches of batoclimab and pre-approval inspection batches of batoclimab which may be used for regulatory submissions and, pending regulatory approval, commercial sale. In addition, Immunovant has a minimum obligation to purchase additional batches of batoclimab in the four-year period of 2026 through 2029. As of March 31, 2025, the remaining minimum purchase commitment related to this agreement was estimated to be approximately $43.6 million, of which $5.5 million, $10.1 million, $14.0 million and $14.0 million is expected to be paid during the fiscal years ending March 31, 2026, 2028, 2029 and 2030, respectively.
Read it in 10-K May 29, 2025 at sec.govopen_in_new
RemovedMD&A
The above purchase commitments do not represent all of our anticipated purchases, but instead represent only the contractually obligated minimum purchases or firm commitments of non-cancelable minimum amounts.
Read it in 10-K May 29, 2025 at sec.govopen_in_new
RemovedMD&A
Net cash (used in) provided by financing activities $ (1,219,794) $419,364 $ 499,462
Read it in 10-K May 29, 2025 at sec.govopen_in_new
RemovedMD&A
In November 2023, the FASB issued ASU 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,” which updates reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. The amendments are effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024. These amendments should be applied retrospectively to all prior periods presented in the financial statements. Beginning with this Annual Report on Form 10-K, we adopted this standard which resulted in incremental segment disclosures. Refer to Note 16, “Segment Information” for disclosure of the information required under ASU 2023-07.
Read it in 10-K May 29, 2025 at sec.govopen_in_new
RewordedMD&A
The increase of $78.5 $101.1 million in program-specific costs was primarily driven by increases of $91.1 $79.1 million related to the anti-FcRn franchise, reflecting the progression of our programs, and $15.4 franchise (of which $39.0 million related to mosliciguat, which was acquired during contractual costs recognized in connection with the year ended March 31, 2024. discontinuation of batoclimab), $16.3 million related to mosliciguat and $15.1 million related to brepocitinib.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
RewordedMD&A
For the year ended March 31, 2025, cash flow from investing activities changed by approximately $7.0 billion to net 2026, cash used in investing activities of decreased by approximately $1.1 billion to $682.3 million compared to $1.8 billion for the year ended March 31, 2025 from net cash provided by investing activities of $5.2 billion for the year ended March 31, 2024. 2025.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
RewordedMD&A
For the year ended March 31, 2024, 2026, cash flow from investing financing activities changed by $5.2 approximately $1.4 billion to net cash provided by investing financing activities of $5.2 billion from net cash used in investing activities of $44.3 $134.2 million for the year ended March 31, 2023. 2026 compared to net cash used in financing activities of $1.2 billion for the year ended March 31, 2025.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
RewordedMD&A
Income (loss) from discontinued operations, net of tax was $373.0 million consists of the gain on sale of subsidiary interests for the year ended March 31, 2025 and reflects the gain on sale of subsidiary interests resulting from the sale of our entire equity interest in our majority-owned subsidiary, Dermavant, to Organon in October 2024, partially offset by Dermavant’s net losses. Dermavant Sciences Ltd.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
RewordedMD&A
Research and development expenses increased This increase was primarily driven by $110.5 million to $550.4 million for the year ended March 31, 2025, compared to $439.9 million for the year ended March 31, 2024, primarily due to increases in program-specific costs of $78.5 million, personnel-related expenses of $22.9 million, share-based compensation of $7.4 million and other expenses of $1.7 million.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
RewordedMD&A
Research and development expenses increased by $110.5 million to $550.4 million for the year ended March 31, 2025, compared to $439.9 million for the year ended March 31, 2024, primarily due to increases in program-specific costs of $78.5 million, personnel-related expenses of $22.9 million, share-based compensation of $7.4 million and other expenses of $1.7 million. 2024.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
RewordedMD&A
For the years ended March 31, 2025, 2024 2026, 2025 and 2023, 2024, we had a net loss losses from continuing operations of $397.9 million and $729.8 million, million and had net income from continuing operations of approximately $4.5 billion and a net loss from continuing operations of $889.1 million, billion, respectively.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
RewordedMD&A
Roivant’s pipeline includes brepocitinib, a potent small molecule inhibitor of JAK1 and TYK2 currently under review at the FDA for the treatment of dermatomyositis and JAK1 also in late stage development for the treatment of dermatomyositis, non-infectious uveitis uveitis, cutaneous sarcoidosis and cutaneous sarcoidosis; lichen planopilaris;
Read it in 10-K May 20, 2026 at sec.govopen_in_new
RewordedMD&A
A summary of general and administrative expense relating to the Cash one-time cash retention bonus award to its employees awarded during the year ended March 31, 2024 (the “Cash Bonus Program Program”) and 2024 Senior Executive Compensation Program is as follows (in thousands):
Read it in 10-K May 20, 2026 at sec.govopen_in_new
RewordedMD&A
Change in fair value of liability instruments was a loss of $47.7 million, a gain of $15.8 million, million and a loss of $46.8 million, and a loss of $18.4 million for the years ended March 31, 2025, 2024 2026, 2025 and 2023, 2024, respectively.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
RewordedMD&A
The change of $27.2 $49.9 million was primarily driven by changes in the public share prices price of our equity investments, including Arbutus, as well as the change in fair value of our investment in Datavant. Datavant, which was driven by growth in forecasted financial performance.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
RewordedMD&A
In October 2022, December 2025, Immunovant completed an underwritten public offering of 12,500,000 26,200,000 shares of its common stock (including 416,667 16,666,666 shares of common stock purchased by us) at a price to the public of $6.00 $21.00 per share, for net proceeds to Immunovant of approximately $70.2 $543.6 million after deducting underwriting discounts and commissions and offering expenses.
Read it in 10-K May 20, 2026 at sec.govopen_in_new